1stOncology™: Cancer Intelligence Service – Page 6058 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

On March 8, 2022 Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, reported that an abstract has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, scheduled for April 8-13 in New Orleans (Press release, Lyell Immunopharma, MAR 8, 2022, View Source [SID1234609998]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The poster presentation being presented at AACR (Free AACR Whitepaper) will highlight the preclinical data characterizing LYL797, Lyell’s first therapeutic candidate incorporating T-cell reprogramming technologies for the treatment of solid tumors. LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. LYL797 incorporates two Lyell technologies designed to address major barriers to successful Adoptive Cell Therapy (ACT): Gen-R, a genetic reprogramming technology that endows T cells with the ability to resist exhaustion, and Epi-R, an epigenetic reprogramming technology that creates populations of T cells with the properties of durable stemness. T cells with properties of durable stemness are able to proliferate, persist, and self-renew with anti-tumor functionality.

"With LYL797 entering clinical development, we are excited to present the preclinical data evaluating our two T-cell reprogramming technologies which are designed to overcome the barriers we believe have impeded the development of more effective cell therapies for patients with solid tumor cancers," said Tina Albertson, MD, PhD, Chief Medical Officer and Head of Development of Lyell. "Reprogramming T cells to be able to resist exhaustion and demonstrate properties of durable stemness is key to our mission to develop cell therapies that can outlast and eradicate hard-to-kill solid tumors."

Details on the poster presentation are below:

Poster Title: LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors
Session: Adoptive Cell Therapy
Abstract Number: 3808
Presentation Date, Time & Location: Tuesday, April 12, 9:00am – 12:30pm, Section 30
Presenter: Spencer Park, PhD, Lyell Immunopharma

The abstract has been posted to the AACR (Free AACR Whitepaper) online itinerary planner. Following the meeting, the abstract will be published in an online-only supplement to the AACR (Free AACR Whitepaper) journal Cancer Research.

Lyell announced U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL797 in December 2021.

Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia

On March 8, 2022 Eucure Biopharma, a wholly owned subsidiary of Biocytogen, reported the first patient dosing for a phase I multi-regional clinical trial (MRCT) of YH002 (anti-OX40 monoclonal antibody, mAb) in combination with YH001 (anti-CTLA-4 mAb) (No. YH002004) in Australia (Press release, Biocytogen, MAR 8, 2022, View Source [SID1234609975]). This phase I MRCT will be conducted in Australia and China.

The clinical trial is an open-label, dose-escalation phase I study designed to evaluate the safety, tolerability and preliminary efficacy of YH002 in combination with YH001 in patients with advanced solid tumors. Pharmacokinetics and immunogenicity of YH001 and YH002 will also be evaluated.

Eucure Biopharma has previously completed mono-dose-escalation studies for YH001 and YH002. The results show that both YH001 and YH002 have good tolerance and safety.

Dr. Yuelei Shen, Chairman and CEO of Biocytogen and Eucure Biopharma, said, "Both YH001 and YH002 are developed from Biocytogen’s evidence-based in vivo efficacy screening platform. Using animal models, we found for the first time, that combination of YH002 and YH001 has very good antitumor activity. We expect the results from animal models can be verified in patients. We are hopeful that these platforms will continue to drive the discovery and development of novel therapeutic antibodies, ADCs and bispecific ADCs for future clinical benefit."

About YH002

YH002 is a recombinant anti-OX40 humanized IgG1 antibody. Targeting OX40 enhances anti-tumor responses both by activating effector T cells and inhibiting or exhausting regulatory T cells (Treg). In preclinical studies, YH002 demonstrated excellent specificity, affinity and safety. In vivo studies using Biocytogen’s humanized mouse models demonstrated improved therapeutic potential of YH002 compared to benchmark antibodies, and indicated promising potential for combination therapy.

About YH001

YH001 is an anti-CTLA-4 monoclonal antibody that aims to enhance the anti-tumor immune response through removal of Treg from the tumor microenvironment. Combination therapies that block multiple inhibitory immune checkpoints (including CTLA-4 and PD-1) are currently considered to be promising treatments for multiple types of tumors, due to their potential to influence the activity of multiple populations of T cells.

J&J in Partnership Talks with Two China Biopharmas

On March 8, 2022 Johnson & Johnson reported that it is currently talking with two China biopharmas about forming partnerships, though it did not name either company (Press release, Johnson & Johnson, MAR 8, 2022, View Source [SID1234609974]). J&J has a very good reason for being interested in China . Four years ago, its subsidiary, Janssen Pharma, formed a $1 billion partnership for Nanjing Legend Bio’s CAR-T multiple myeloma therapy. At the time Legend wasn’t particularly well known, but its CAR-T posted very high efficacy rates in a early trial. One week ago, Carvykti (cilta-cel) was approved for a US launch.

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

On March 8, 2022 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, reported that the Company will present a poster and three oral presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place between April 8-13, 2022 in New Orleans, Louisiana and virtually (Press release, C4 Therapeutics, MAR 8, 2022, View Source [SID1234609972]).

Presentations at AACR (Free AACR Whitepaper) Annual Meeting 2022:

Title: CFT7455: Pharmacokinetic (PK) Profile of a Novel IKZF1/3 Degrader, CFT7455, Enables Significant Potency Advantage over Other IKZF1/3 Degraders in Models of Multiple Myeloma (MM) and the Results of the Initial Treatment Cohort from a First-in-Human (FIH) Phase 1/2 Study of CFT7455 in MM
Abstract Number: CT186, Poster
Time: Tuesday, April 12, 2022, 9:00 AM – 12:30 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 33
Presenter: Sagar Lonial, M.D., FACP, chief medical officer, Winship Cancer Institute of Emory University; professor and chair, department of hematology and medical oncology, Emory University School of Medicine

Title: The discovery and characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma
Abstract Number: 7922, Oral
Time: Monday, April 11, 2022, 10:15 AM -11:45 AM CT
Location: New Orleans Convention Center, La Nouvelle Orleans A-B
Session: New Drugs on the Horizon: Part 3
Presenter: Jim Henderson, Ph.D., vice president of chemistry, C4 Therapeutics

Title: The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers
Abstract Number: 7756, Oral
Time: Sunday, April 10, 2022, 3:00 PM – 4:30 PM CT
Location: New Orleans Convention Center, La Nouvelle Orleans A-B
Session: New Drugs on the Horizon: Part 2
Presenter: Kate Jackson, Ph.D., senior director of chemistry, C4 Therapeutics
Title: Preclinical Evaluation of CFT1946 as a Selective Degrader of Mutant BRAF for the Treatment of BRAF Driven Cancers
Abstract Number: 2158, Oral
Time: Monday, April 11 2:30 PM – 4:30 PM CT
Location: New Orleans Convention Center, Great Hall AD
Session: Emerging New Anticancer Agents
Presenter: Mathew Sowa, Ph.D., senior director, proteomics and ubiquitin proteasome system biology, C4 Therapeutics
In addition to these data presentations, Chris Nasveschuk, senior vice president, chemistry, will be participating in the Targeted Protein Degradation: Access to New Medicines by Drugging Challenging Targets educational session on Friday, April 8, 2022 from 5:30 PM to 5:50 PM CT.

Investor Webcast Information
C4T will host an investor webcast on Friday, April 8, 2022 at 2 PM ET to discuss the CFT7455 Cohort A clinical data that will be presented at the AACR (Free AACR Whitepaper) Annual Meeting. The webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be available on C4T’s website for 30 days following the event.

Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies

On March 8, 2022 Orbit Discovery (Orbit), a ground-breaking peptide discovery company reported the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry (Press release, WuXi AppTec, MAR 8, 2022, View Source [SID1234609952]).

Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid timeframe. Orbit will also utilise other capabilities within WuXi AppTec, in particular their expertise in cell line and assay development and biophysical analysis.

Related Stories
FUJIFILM Healthcare Europe presents ECHELON Smart Plus
Measuring T cell responses to SARS-CoV-2 vaccination and infection in healthcare workers with two different assays
CDC releases new materials for healthcare professionals as part of the Hear Her campaign
Incorporating these capabilities into the Orbit platform will enable functional assays to be developed against a wider range of targets, facilitating direct functional screens using novel bead-based technologies and microfluidics.

This is the first strategic technology link Orbit has penned since its formation in 2016. The partnership underlines the commitment of the new management team to deliver ground-breaking technology and broader capabilities to the Partners engaged in applying the Company’s technology for the discovery of peptide therapeutic leads.

"We aim to move Orbit to the forefront of peptide discovery, and relationships such as this help us leverage expertise that would take far longer to grow organically. We see the partnership with WuXi AppTec as being a key relationship and a great asset to our current Partners, and Partners of the future." He added: "We see particular value in the development and manufacturing platform of WuXi AppTec, that will enable us to generate peptides at small or large scale that incorporate chemical modifications to facilitate peptide optimisations and the journey towards a therapeutic candidate."

Dr Neil Butt, Chief Executive Officer of Orbit Discovery

"We are very pleased to have the opportunity to support Orbit Discovery and its research partners" commented Dr Dave Madge, VP Discovery Services at WuXi AppTec. "We see substantial synergies between the Orbit technology for peptide discovery and our platform for optimisation, characterisation and manufacture of novel peptide therapeutics."